New Delhi, April 11 -- Sun Pharmaceutical Industries Ltd, which has been embroiled in a patent lawsuit in the US since last year over its specialty drug Leqselvi, received a favourable ruling from a court, paving the way for the drug's launch in America, it said on Thursday.

The US Court of Appeals for the Federal Circuit on 9 April vacated a preliminary injunction on Leqselvi's launch, lifting restrictions on the launch, Sun Pharma company said in a regulatory filing.

The Mumbai-based company had received approval from the US Food and Drug Administration for Leqselvi, a drug used to treat alopecia areata that causes hair loss or baldness, in July 2024.

However, soon after the regulator's approval, American biopharma company Incyte Cor...